WO2004071468A3 - Short immunomodulatory oligonucleotides - Google Patents

Short immunomodulatory oligonucleotides Download PDF

Info

Publication number
WO2004071468A3
WO2004071468A3 PCT/US2004/000789 US2004000789W WO2004071468A3 WO 2004071468 A3 WO2004071468 A3 WO 2004071468A3 US 2004000789 W US2004000789 W US 2004000789W WO 2004071468 A3 WO2004071468 A3 WO 2004071468A3
Authority
WO
WIPO (PCT)
Prior art keywords
short
immunomodulatory oligonucleotides
relates
immune system
oligonucleotides
Prior art date
Application number
PCT/US2004/000789
Other languages
French (fr)
Other versions
WO2004071468A2 (en
Inventor
Sudhir Agrawal
Ekambar Kandimalla
Dong Yu
Lakshmi Bhagat
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Priority to EP04701751A priority Critical patent/EP1594432A4/en
Priority to CA002512934A priority patent/CA2512934A1/en
Priority to MXPA05008360A priority patent/MXPA05008360A/en
Priority to AU2004210625A priority patent/AU2004210625A1/en
Priority to JP2006536535A priority patent/JP2007531510A/en
Publication of WO2004071468A2 publication Critical patent/WO2004071468A2/en
Publication of WO2004071468A3 publication Critical patent/WO2004071468A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Abstract

The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
PCT/US2004/000789 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides WO2004071468A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04701751A EP1594432A4 (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides
CA002512934A CA2512934A1 (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides
MXPA05008360A MXPA05008360A (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides.
AU2004210625A AU2004210625A1 (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides
JP2006536535A JP2007531510A (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/361,111 US7354907B2 (en) 2003-02-07 2003-02-07 Short immunomodulatory oligonucleotides
US10/361,111 2003-02-07

Publications (2)

Publication Number Publication Date
WO2004071468A2 WO2004071468A2 (en) 2004-08-26
WO2004071468A3 true WO2004071468A3 (en) 2007-01-18

Family

ID=32824138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000789 WO2004071468A2 (en) 2003-02-07 2004-01-13 Short immunomodulatory oligonucleotides

Country Status (8)

Country Link
US (2) US7354907B2 (en)
EP (1) EP1594432A4 (en)
JP (1) JP2007531510A (en)
KR (1) KR20050098302A (en)
AU (1) AU2004210625A1 (en)
CA (1) CA2512934A1 (en)
MX (1) MXPA05008360A (en)
WO (1) WO2004071468A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2004064782A2 (en) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
DE10328813B4 (en) * 2003-06-20 2006-04-13 Epigenomics Ag Method for the investigation of cytosine methylations in DNA sequences using triplex-forming oligomers
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
AU2005257938B2 (en) * 2004-06-15 2010-11-11 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2011028550A1 (en) * 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics
WO2014110081A1 (en) * 2013-01-08 2014-07-17 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CN106535876B (en) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP2017537619A (en) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
CN106754739A (en) * 2016-12-30 2017-05-31 天津三箭生物技术股份有限公司 Mouse anti human P53 monoclonal antibodies and secrete the hybridoma cell strain of the monoclonal antibody
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108178698A (en) * 2018-03-19 2018-06-19 联保作物科技有限公司 Complex composition, agricultural bacteriocide and its application containing antibiotic in pyrimidine nucleoside class and dipotassium hydrogen phosphate
CN113631564A (en) * 2019-03-28 2021-11-09 味之素株式会社 Method for producing oligonucleotide having phosphorothioate moiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026757A2 (en) * 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2003057822A2 (en) * 2001-10-24 2003-07-17 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP2314693A3 (en) * 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CA2398432C (en) * 2000-01-26 2012-06-19 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
CA2407942A1 (en) * 2000-05-01 2001-11-08 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US20040097718A1 (en) * 2000-07-19 2004-05-20 Pearson James D. Complete nucleotide sequence of staphlococcus aureus ribosomal protein gene, s20 and methods for the identification of antibacterial substances
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en) * 2001-05-04 2003-07-10 Dong Yu Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1393745A1 (en) * 2002-07-29 2004-03-03 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
WO2004064782A2 (en) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA05012421A (en) 2003-05-16 2006-02-22 Hybridon Inc Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents.
KR101137572B1 (en) * 2003-06-11 2012-05-30 이데라 파마슈티칼즈, 인코포레이티드 Stabilized immunomodulatory oligonucleotides
EP1648913A4 (en) * 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
KR101138131B1 (en) * 2003-12-08 2012-04-23 이데라 파마슈티칼즈, 인코포레이티드 Modulation of immunostimulatory properties by small oligonucleotide-based compounds
US20050222072A1 (en) * 2004-02-20 2005-10-06 Hybridon, Inc. Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
AU2005257938B2 (en) * 2004-06-15 2010-11-11 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
WO2006011160A1 (en) * 2004-06-28 2006-02-02 Alembic Limited Process for the preparation of azithromycin monohydrate isopropanol clathrate
EP1734583A1 (en) * 2005-06-14 2006-12-20 Photonis-DEP B.V. Electron bombarded image sensor array device and its manufactoring method
US20070093439A1 (en) * 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US7776834B2 (en) * 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2008006004A (en) * 2005-11-07 2008-10-01 Idera Pharmaceuticals Inc Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides.
MX2008008279A (en) * 2005-12-20 2009-03-04 Idera Pharmaceuticals Inc Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments.
AU2006336242A1 (en) 2005-12-20 2007-07-26 Idera Pharmaceuticals, Inc. Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
MX2009003398A (en) * 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
CN101610671A (en) 2006-12-12 2009-12-23 艾德拉药物股份有限公司 Synthetic TLR9 activator
KR20100053598A (en) 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Novel synthetic agonists of tlr9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026757A2 (en) * 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2003057822A2 (en) * 2001-10-24 2003-07-17 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BHAGAT L. ET AL.: "CpG penta- and hexaddeoxyribonucleotides as potent immunomodulatory agents", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 300, no. 4, 24 January 2003 (2003-01-24), pages 853 - 861, XP002989072 *
KANDIMALLA E.R. ET AL.: "A dinucleotide motif is oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition with CpG motif", PNAS, vol. 100, no. 24, 25 November 2003 (2003-11-25), pages 14303 - 14308, XP002990545 *
KANDIMALLA E.R. ET AL.: "Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity", BIOCONJUGATE CHEM., vol. 13, 2002, pages 966 - 974, XP002989075 *
KANDIMALLA E.R. ET AL.: "Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles", NUCLEIC ACIDS RESEARCH, vol. 31, no. 9, 2003, pages 2393 - 2400, XP002989074 *
KANDIMALLA E.R. ET AL.: "Towards optimal design of second generation immunomodulatory oligonucleotides", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 4, no. 2, 2002, pages 122 - 129, XP009062237 *
KLINMAN D.M.: "Therapeutic applications of CpG-containing oligodeoxynucleotides", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 8, 1998, pages 181 - 184, XP002128519 *
LI Y. ET AL.: "Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HbsAg in mice", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 5, 2005, pages 981 - 991, XP003007080 *
MARSHALL J.D. ET AL.: "Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells", NUCLEIC ACIDS RESEARCH, vol. 31, no. 17, 2003, pages 5122 - 5133, XP003007082 *
YU D. ET AL.: "Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 2585 - 2588, XP004219767 *
YU D. ET AL.: "Immunomers'-novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents", NUCLEIC ACIDS RESEARCH, vol. 30, no. 20, 15 October 2002 (2002-10-15), pages 4460 - 4469, XP002903989 *
YU D. ET AL.: "Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 297, 2002, pages 83 - 90, XP002989076 *
ZHAO Q. ET AL.: "Immunosimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleotide", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, 2000, pages 1051 - 1054, XP004204603 *
ZHU F.-G. ET AL.: "Modulation of ovalbumin-induced Th2 response by second-generation immunomodulatory oligonucleotides in mice", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 4, 2004, pages 851 - 862, XP003007081 *

Also Published As

Publication number Publication date
US20040156825A1 (en) 2004-08-12
AU2004210625A1 (en) 2004-08-26
WO2004071468A2 (en) 2004-08-26
KR20050098302A (en) 2005-10-11
JP2007531510A (en) 2007-11-08
EP1594432A4 (en) 2008-08-06
CA2512934A1 (en) 2004-08-26
EP1594432A2 (en) 2005-11-16
MXPA05008360A (en) 2005-11-04
US20090010938A1 (en) 2009-01-08
US7851454B2 (en) 2010-12-14
US7354907B2 (en) 2008-04-08

Similar Documents

Publication Publication Date Title
WO2004071468A3 (en) Short immunomodulatory oligonucleotides
WO2001012804A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2001055370A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
HK1034039A1 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1208085A4 (en) Benzanilides as potassium channel openers
WO2001083503A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2003101397A3 (en) Tetravalent dengue vaccines
EP2199299A3 (en) Antisense modulation of survivin expression
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2003052072A3 (en) Antisense modulation of estrogen receptor alpha expression
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2005051423A3 (en) Methods and agents for immune modulation and methods for identifying immune modulators
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
EP1165145A4 (en) Antisense modulation of mdmx expression
AU2003219046A1 (en) Cationic polymers and the use thereof in cosmetic formulations
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2005115456A3 (en) METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004210625

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2512934

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004210625

Country of ref document: AU

Date of ref document: 20040113

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004210625

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008360

Country of ref document: MX

Ref document number: 2006536535

Country of ref document: JP

Ref document number: 1020057014457

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004701751

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057014457

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004701751

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)